Brought to you by 
Cara and Alza to develop early-stage pain compound; terminated
09 Dec 2013
Executive Summary
Analgesic company Cara Therapeutics formed a worldwide licensing agreement with Alza, a wholly-owned subsidiary of Johnson & Johnson, to develop the Phase I acute pain and inflammation candidate CR665.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com